Moderna skyrockets 16% to record high after FDA clears coronavirus vaccine for phase 2 study

6:18am PDT - May 7th, 2020    moderna - Business Insider

• Moderna stock surged as much as 16% early Thursday after the company announced its coronavirus vaccine candidate received FDA approval for phase 2 trials.
• The biotech firm is preparing for a phase 3 study to begin in the early summer with th…